Kohli Laboratory News

The liver’s natural regeneration capabilities, unique among the body’s organs, enable many pediatric liver transplants.

A recent study led by Principal Investigator Michael Goran, PhD, and Rachel Schenker, MD, a Fellow in the CHLA Liver Transplant Program, has found a novel combination of plasma-based biomarkers that

A new class of drugs can relieve itching for cholestatic childhood liver disease and potentially lengthen time until a liver transplant is necessary.

Senior Program Manager Casey Covarrubias discusses the services offered through the program, which supports junior researchers with their NIH grant applications.

Receiving a liver transplant means also living with the possibility of rejection. Transplant rejection occurs when the body’s immune system attacks the new organ. This risk is highest in the first

Clinical Research Coordinator Sirikorn Boonsawat explored careers in pharmacy and law before finding her niche working with Dr. Rohit Kohli at CHLA.

After enduring years of severe abdominal pain, a teenager becomes the first pediatric patient in Southern California to undergo a rare procedure called TPIAT.

Dr. Bhattacharjee is investigating potential therapies for the most severe form of fatty liver disease: metabolic dysfunction-associated steatohepatitis.